Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
D000069594:Abatacept; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000096:biosynthesis; D001402:B-Lymphocytes / Q000276:immunology; D023201:CD40 Ligand / Q000378:metabolism; D060908:CTLA-4 Antigen; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D018450:Disease Progression; D005260:Female; D006968:Hypersensitivity, Delayed / Q000628:therapy; D018796:Immunoconjugates; D007074:Immunoglobulin G / Q000096:biosynthesis; D020382:Interleukin-18 / Q000037:antagonists & inhibitors* / Q000276:immunology; D007700:Kinetics; D008213:Lymphocyte Activation; D020720:Myasthenia Gravis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D011978:Receptors, Nicotinic / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000096:biosynthesis